HIV-1 Vaccine Development After STEP

被引:84
|
作者
Barouch, Dan H. [1 ,2 ]
Korber, Bette [3 ,4 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02115 USA
[2] Ragon Inst MGH MIT & Harvard, Boston, MA USA
[3] Los Alamos Natl Lab, Los Alamos, NM USA
[4] Santa Fe Inst, Santa Fe, NM 87545 USA
来源
ANNUAL REVIEW OF MEDICINE | 2010年 / 61卷
基金
美国国家卫生研究院;
关键词
HIV-1; viral diversity; antigen design; T cell vaccines; antibody vaccines; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; SUBTYPE-B; IMMUNOGENICITY EVALUATION; ENVELOPE GLYCOPROTEIN; VIRAL REPLICATION; LYMPHOCYTE ESCAPE; PHASE-1; SAFETY;
D O I
10.1146/annurev.med.042508.093728
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Despite more than 2 5 years of concerted worldwide research, the development of a safe and effective HIV-1 vaccine remains elusive. Prototype antibody-based and T cell-based HIV-1 vaccines have failed to show efficacy in clinical trials to date. Next-generation HIV-1 vaccine candidates are in various stages of preclinical and clinical development, but key scientific obstacles pose major challenges for the field. Critical hurdles include the enormous global diversity of the virus and the challenges associated with generating broadly reactive neutralizing antibody and cellular immune responses. We review the current state of the HIV-1 vaccine field and outline strategies that are being explored to overcome these roadblocks.
引用
收藏
页码:153 / 167
页数:15
相关论文
共 50 条
  • [21] THE DEVELOPMENT OF A VACCINE AGAINST HIV-1 - PROGRESS AND OBSTACLES
    EMINI, EA
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (11) : 1359 - 1360
  • [22] Improved outlook on HIV-1 prevention and vaccine development
    Vasan, Sandhya
    Michael, Nelson L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (08) : 983 - 994
  • [23] Designing boosting immunogens for HIV-1 vaccine development
    Liu, Qingbo
    CELL HOST & MICROBE, 2024, 32 (05) : 632 - 634
  • [24] HIV-1 polymorphism: A challenge for vaccine development - A review
    Morgado, MG
    Guimaraes, ML
    Galvao-Castro, B
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2002, 97 (02): : 143 - 150
  • [25] Viral diversity as a challenge to HIV-1 vaccine development
    Carr, Jean K.
    CURRENT OPINION IN HIV AND AIDS, 2006, 1 (04) : 294 - 300
  • [26] The Significance of HIV-1 Genetic Diversity for Vaccine Development
    Thomson, Michael M.
    CURRENT HIV RESEARCH, 2010, 8 (08) : 577 - U5
  • [27] Correlations Between HIV-1 Clades and HIV-1 Antibody Neutralization Sensitivity: Significant for Vaccine Development?
    van Gils, Marit J.
    Schuitemaker, Hanneke
    CURRENT HIV RESEARCH, 2010, 8 (08) : 579 - 586
  • [28] Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine
    Cafaro, Aurelio
    Tripiciano, Antonella
    Sgadari, Cecilia
    Bellino, Stefania
    Picconi, Orietta
    Longo, Olimpia
    Francavilla, Vittorio
    Butto, Stefano
    Titti, Fausto
    Monini, Paolo
    Ensoli, Fabrizio
    Ensoli, Barbara
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 : S13 - S29
  • [29] The HIV-1 vaccine race
    Ho, DD
    Huang, YX
    CELL, 2002, 110 (02) : 135 - 138
  • [30] Immunomodulatory nanoparticle as a novel platform for HIV-1 vaccine development
    Zhao, T.
    Sicard, T.
    Julien, J-P.
    Treanor, B.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1663 - 1664